Why Sponsors Choose Some Sites Over Others: The CRO Site Selection Process Explained

Most sites experience site selection as a black box. A feasibility questionnaire goes out, weeks pass, and then a yes or a form-letter no arrives with no explanation either way. The process on the other side of that silence is not mysterious. It runs through a defined sequence of stages, and each one weighs specific things. Here is what actually happens between the questionnaire landing in your inbox and the final site list going out.

The Process Starts Before You See a Questionnaire

By the time a feasibility questionnaire reaches your inbox, your site has already cleared a first filter: it made the candidate list. Sponsors and CROs build that longlist from a small set of recurring sources. Internal databases of investigators who ran prior studies. A CRO's preferred site network. Conference relationships from ACRP and SCRS meetings. Increasingly, claims or EHR-derived data showing where the target patient population is actually treated.

A site with no history in any of those channels is not being rejected. It is simply not being seen. That distinction matters, because the fix is different. It is not about writing a better questionnaire response. It is about showing up in the places sponsors and CROs already look, including an accurate, current ClinicalTrials.gov history.

Once the longlist exists, the sponsor or the CRO's feasibility team sends a structured questionnaire to every candidate site alongside a protocol synopsis. That is where the visible part of the process begins.

Stage One: The Questionnaire Goes Out to the Full Candidate List

The questionnaire is sent to every site on the longlist at roughly the same time, not one at a time. That matters for how a site should read the silence that follows submission. A slow reply is rarely a signal about your specific answers. It usually means the feasibility team is still collecting responses from the full candidate pool before anyone gets scored.

What gets asked is fairly consistent across sponsors: patient population estimates, staffing plans, prior trial history, regulatory file state, and current competing studies. The detail each answer needs, and the documentation that strengthens it, is covered in full in our guide to preparing a site feasibility questionnaire.

Stage Two: Answers Get Scored Against a Rubric, Not Read One at a Time

Questionnaires are not read and judged individually as they arrive. Larger sponsors and CROs score every returned questionnaire against the same weighted rubric, often reviewed by a site selection committee that includes the feasibility team, a clinical operations lead, and sometimes a medical monitor. That structure exists specifically to keep the decision consistent and auditable across dozens of candidate sites.

A 2019 survey of 43 biopharmaceutical companies and CROs, published in the journal Trials, asked decision-makers directly what they weigh most in that scoring. The answer was consistent and, for most sites, counterintuitive. Recruitment-related factors outweighed everything else: 88% of respondents said they would rather work with a site expected to enroll 10% faster than one offering a 20% lower cost. Asked to rank the single most important individual factor, 42% chose having patients ready to enroll immediately after the site initiation visit, well ahead of data quality (25%), reachable staff (23%), fast contract turnaround (6%), and equipment (1%).

The same study found experience matters less than most sites assume. 75% of respondents said they would work with an inexperienced site if it had access to the right patient population, and 52% had already chosen an inexperienced site over an experienced one based on demonstrated commitment. Experience carries more weight in early-phase studies than in Phase 3, where patient access tends to decide the outcome.

The practical read for a site: a strong facility tour and an impressive CV do not move this scorecard nearly as much as a specific, evidenced patient volume estimate does. Running a structured enrollment feasibility report before the questionnaire arrives is what turns a patient estimate from a guess into evidence.

Stage Three: A Prestudy Visit Confirms What the Paper Said

Sites that score well on paper move to a prestudy visit, sometimes called a site assessment visit. This is a distinct step from the site qualification visit that happens later, after a site is formally selected. A prestudy visit is still part of the evaluation itself. A qualification visit is preparation for activation.

During the prestudy visit, a feasibility associate or clinical research associate verifies what the questionnaire claimed. Physical space, equipment, investigational product storage, and a direct conversation with the PI and coordinator to confirm the patient population estimate holds up under questioning. A site whose answers do not match what the visit finds loses credibility fast, regardless of how the questionnaire scored.

Once a site clears this stage and is formally selected, the next visit it sees is the site qualification visit, which serves a different purpose: confirming activation readiness rather than deciding selection. Our guide on what sponsors and CROs check during a site qualification visit covers that stage in detail.

Stage Four: The Final List Balances the Whole Portfolio, Not Just One Site

A site can pass every individual stage and still not make the final list. That is because the last decision is not made site by site. It is made across the whole candidate pool at once, balancing enrollment capacity against geographic and demographic diversity, competing-trial exposure, and budget.

A site that scored well can still be cut if a sponsor already selected a site in the same patient catchment area. Two strong sites competing for the same regional patient pool would both underperform their individual projections, so the sponsor keeps one and passes on the other. That outcome has nothing to do with the passed-over site's quality. It is a portfolio math problem, and it is the single most common reason a well-qualified site does not hear back with an explanation.

Understanding this stage reframes what "no" usually means. It is rarely a verdict on the site. More often it is a statement about where that site sits relative to every other candidate the sponsor is weighing at the same time.

Why Sites Rarely Get a Real Answer, and What to Do With the Silence

Sponsors and CROs are managing dozens of candidate sites per study and do not have the bandwidth to give individualized feedback to every site that is not selected. That is an operational reality, not a judgment on any one site. The standard notification is a brief confirmation either way, with no elaboration.

A site not selected for one study is frequently retained on file for the next one in the same therapeutic area. Nothing about not being chosen this time removes a site from future consideration, and a site that keeps its questionnaire answers, patient volume data, and regulatory files current is easier to reconsider quickly when the next study opens.

The most useful response to an unexplained no is not to guess at what went wrong. It is to keep the same evidence current for the next opportunity: an accurate registry history, an up-to-date patient population estimate, and a documented enrollment track record from the studies already running.

What the Rubric Rewards, in Practice

The 2019 Trials survey findings point to the same conclusion at every stage of this process: recruitment capability, not facilities or cost, decides most selection outcomes. A site entering the process with a documented, quantified enrollment record is answering the exact question the rubric is built to score.

Clinical Enroll works with sites on exactly this evidence. Our model runs on a randomization commitment: a specific number of randomized patients for the study, re-run at no cost if the target is not met. What that looks like in practice, in narrow-eligibility protocols similar to what most sponsors are screening for, is documented below.

For the full playbook on positioning a site before a study opens, including preferred site networks and how to build the kind of sponsor relationship that shortens this whole process, see our guide on how sites get selected for clinical trials.